Yap, Timothy A.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 3,634

State-of-the-art strategies for targeting the DNA damage response in cancer

Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology

PARP inhibition in cancer therapyDNA Repair Mechanisms

Cited by 1,189

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 1,033

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 903

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 543

Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Sarker, D., Reid, A. H. M., Yap, T. A., & de Bono, J. S. (2009) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 366

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 349

Novel Insights into Mesothelioma Biology and Implications for Therapy

Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 324

Development of PARP and immune-checkpoint inhibitor combinations

Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 239

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer

Yap, T. A., Macklin-Doherty, A., & Popat, S. (2017) · European Journal of Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 38

AVID200, first‐in‐class TGF‐beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose‐escalation study in patients with advanced solid tumors

Yap, T. A., Lakhani, N. J., Araujo, D. V., Rodon Ahnert, J., Chandana, S. R., Sharma, M., Denis, J.-F., Gruosso, T., Tremblay, G., O'Connor, M., et al. (2020) · Journal of Clinical Oncology

TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers

Cited by 26

Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer

Glassman, D., Kim, M. S., Spradlin, M., Badal, S., Taki, M., Bhattacharya, P., Dutta, P., Kingsley, C. V., Foster, K. I., Animasahun, O., et al. (2023) · iScience

Cancer, Hypoxia, and MetabolismOvarian cancer diagnosis and treatment

Cited by 15